Xspray Pharma AB (publ) (LON:0GHZ)

Market Cap	91.95M -4.7%
Revenue (ttm)	196.23K
Net Income	-13.09M
EPS	-0.33
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,019
Open	26.00
Previous Close	n/a
Day's Range	25.35 - 26.00
52-Week Range	24.28 - 61.40
Beta	0.82
Analysts	n/a
Price Target	n/a
Earnings Date	May 6, 2026

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partn...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 24
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GHZ

Financial Performance

Financial numbers in SEK